ClinicalTrials.gg
DrugBiological

Mosunetuzumab clinical trials

Also written RO7030816, Lunsumio and BTCT4465A.

studies test it
47
open now
27
in phase 3
5
first study started
2015

How each study uses mosunetuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the mosunetuzumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Dec 2022 · LUNSUMIO VELO · BLA 761263 (FDA, Drugs@FDA)
European Union
3 Jun 2022 · Lunsumio · EMEA/H/C/005680 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Mosunetuzumab
39
Mosunetuzumab (IV)
3
Mosunetuzumab (SC)
3
Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A
2
CD20/CD3 BiMAb BTCT4465A
2

Brand

Lunsumio
7

Development codes

RO7030816
9
BTCT4465A
6
RG 7828
2

Studies by the year they started

46 studies that test it; most in 2024 (12); 1 more planned to start later

Studies that test mosunetuzumab, by start year
YearStudies
20151
20181
20192
20202
20213
202210
20236
202412
20254
20265

Who runs them

Industry 14 · Other 33

Hoffmann-La Roche (11) · University of Washington (4) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (3) · Washington University School of Medicine (2) · The Lymphoma Academic Research Organisation (2) · Genentech, Inc. (2) · SWOG Cancer Research Network (2)

Often tested with

Tested in the same studies.

Polatuzumab vedotin (9) · Lenalidomide (6) · Rituximab (2) · Glofitamab (2) · Zanubrutinib (2) · Acalabrutinib (2) · Pirtobrutinib (2) · Tafasitamab (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 10, 1 in phase 3

Studies that test mosunetuzumab, phase 3 first.

Studies

Open first, then newest update. How each study uses mosunetuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 47

See all 47 studies that test mosunetuzumab →

Given beside what is tested · 7 — mosunetuzumab is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call mosunetuzumab · ClinicalTrials.gg INT002162

  • MeSH (NLM) C000731929mosunetuzumabOne source NLM
  • UNII (FDA) LDJ89SS0YGMOSUNETUZUMABConfirmed FDA, NLM
  • NCI Thesaurus C129691MosunetuzumabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.